Boehringer Ingelheim Launches New Site for TIA Sufferers
Rather than ignore its aging mini-stroke medication Aggrenox, BI has shifted marketing to education by launching an unbranded site dedicated to informing sufferers about transient ischemic attacks, better known as TIA.
This week, Boehringer Ingelheim announced the launch of its new unbranded Web site for sufferers of transient ischemic attack (TIA) or mini-stroke. Talk About TIA (www.talkabouttia.com) is a text-driven, simple to navigate Web site that features everything from a symptoms checklist to a risk analysis. However, beneath the education information is an interactive Flash tool called a Symptoms Map that shows visitors the areas of the body TIA can affect. The user simply chooses a male or female figure and clicks on pulsating pain points to read about potential symptoms.
“We try to be very patient-friendly because we know that there are a lot of sufferers who are undiagnosed,” said Bill Mok, director of marketing for Aggrenox at BI. “We created the Symptoms Map to get the signs and symptoms out there.”
The site was established in tandem with the National Stroke Association to serve the 240,000 people diagnosed with TIA, according to Mok.
BI currently markets Aggrenox, an extended-release combination capsule (aspirin/dipyridamole), for stroke prevention after TIA, but chose to make the new site unbranded in order to reach more patients. The Aggrenox site is still active, and offers additional TIA information as well as risk indications.
BI currently has no plans to include a social networking component on Talk About TIA; however, the company is accepting testimonials from patients to be posted in the future.
Mok told Pharm Exec that BI will not purchase online keywords to promote the site, but is engaging in a traditional marketing campaign leveraging NSA’s network of physicians.
Boehringer was one of the 14 pharma firms slapped with FDA warning letters last week for improper online search advertising.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
